Strong Solvency and Capital Structure: At the end of the third quarter of 2024, Chemed reported cash and cash equivalents of $238.5 million and no debt on the balance sheet. In addition, the company repurchased 100,000 shares of Chemed stock for $57.8 million, which equates to a cost of $578.21 per share, and had approximately $161.8 million of remaining share repurchase authorization under its plan. Chemed also maintains a solid track record of dividend payments, with a five-year annualized dividend growth of 6.75%.